Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Survivorship as an element of clinical trials in ovarian cancer.

× No keyword cloud information.

25 in total

1. Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5.

Authors: M A Bookman; B E Greer; R F Ozols
Journal: Int J Gynecol Cancer Date: 2003 Nov-Dec Impact factor: 3.437

2. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.

Authors: David S P Tan; Christian Rothermundt; Karen Thomas; Elizabeth Bancroft; Rosalind Eeles; Susan Shanley; Audrey Ardern-Jones; Andrew Norman; Stanley B Kaye; Martin E Gore
Journal: J Clin Oncol Date: 2008-10-27 Impact factor: 44.544

3. Impact of age on outcome in patients with advanced ovarian cancer treated within a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).

Authors: Pauline Wimberger; Nils Lehmann; Rainer Kimmig; Alexander Burges; Werner Meier; Berit Hoppenau; Andreas du Bois
Journal: Gynecol Oncol Date: 2005-09-29 Impact factor: 5.482

4. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?

Authors: D S Chi; E L Eisenhauer; J Lang; J Huh; L Haddad; N R Abu-Rustum; Y Sonoda; D A Levine; M Hensley; R R Barakat
Journal: Gynecol Oncol Date: 2006-05-22 Impact factor: 5.482

5. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.

Authors: Bryan T J Hennessy; Kirsten M Timms; Mark S Carey; Alexander Gutin; Larissa A Meyer; Darl D Flake; Victor Abkevich; Jennifer Potter; Dmitry Pruss; Pat Glenn; Yang Li; Jie Li; Ana Maria Gonzalez-Angulo; Karen Smith McCune; Maurie Markman; Russell R Broaddus; Jerry S Lanchbury; Karen H Lu; Gordon B Mills
Journal: J Clin Oncol Date: 2010-07-06 Impact factor: 44.544

6. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO).

Authors: Andreas du Bois; Alexander Reuss; Eric Pujade-Lauraine; Philipp Harter; Isabelle Ray-Coquard; Jacobus Pfisterer
Journal: Cancer Date: 2009-03-15 Impact factor: 6.860

7. Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment.

Authors: J M Del Campo; E Felip; D Rubio; R Vidal; B Bermejo; R Colomer; V Zanon
Journal: Gynecol Oncol Date: 1994-04 Impact factor: 5.482

8. Multivariate analysis for prognostic significance of histologic subtype, GST-pi, MDR-1, and p53 in stages II-IV ovarian cancer.

Authors: K Ikeda; K Sakai; R Yamamoto; H Hareyama; N Tsumura; H Watari; M Shimizu; H Minakami; N Sakuragi
Journal: Int J Gynecol Cancer Date: 2003 Nov-Dec Impact factor: 3.437

9. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.

Authors: William E Winter; G Larry Maxwell; Chunqiao Tian; Michael J Sundborg; G Scott Rose; Peter G Rose; Stephen C Rubin; Franco Muggia; William P McGuire
Journal: J Clin Oncol Date: 2007-11-19 Impact factor: 44.544

10. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.

Authors: William E Winter; G Larry Maxwell; Chunqiao Tian; Jay W Carlson; Robert F Ozols; Peter G Rose; Maurie Markman; Deborah K Armstrong; Franco Muggia; William P McGuire
Journal: J Clin Oncol Date: 2007-08-20 Impact factor: 44.544